301257 SMO Clinplus
- 29.30
- -0.78-2.59%
SMO Clinplus News
Prius: An indicative announcement on the 2022 Restricted Stock Incentive Plan granted for the first time, and the listing and circulation of restricted shares during the lifting of the sales restrictions period
Prius: Announcement on Adjusting the Repurchase Price and Quantity of the 2022 Restricted Stock Incentive Plan
Prius: Legal Opinion of Beijing Guofeng Law Firm on the 2022 Restricted Stock Incentive Plan to Prius (Shanghai) Pharmaceutical Technology Development Co., Ltd. was granted for the first time part of the second period of lifting sales restrictions, achievements in lifting sales restrictions, repurchase price adjustments, and repurchase cancellation matters
Prius: Announcement on the 2022 Restricted Stock Incentive Plan for the first time granting some of the achievements of lifting sales restrictions during the second period of lifting sales restrictions
Prius: Announcement on the Repurchase and Cancellation of Some Restricted Shares in the 2022 Restricted Stock Incentive Plan
Prius: Supervisory Board\'s Review Opinions on Matters Related to the 2022 Restricted Stock Incentive Plan
Prius: Announcement on the completion of the implementation of the company\'s shareholders\' holdings reduction plan
Prius: Pre-disclosure Notice on the Company\'s Shareholders\' Shareholders\' Shareholdings Reduction
Prius: 2024 Semi-Annual Equity Distribution Implementation Notice
Prius: An indicative announcement on the 2022 Restricted Stock Incentive Plan reservation grant for the first time to lift the sales restriction period and lift the listing and circulation of restricted shares
Prius: Supervisory Board\'s Review Opinions on the 2022 Restricted Stock Incentive Plan on the List of Incentives Reserved to Grant Part 1 of the Achievements in Releasing the Sales Restriction Period to Release the Sales Restriction Conditions
Prius: Announcement on the 2022 Restricted Stock Incentive Plan reserves and grants some of the first achievements to lift sales restrictions during the period of lifting sales restrictions
Prius: Legal Opinion of Beijing Guofeng Law Firm on the 2022 Restricted Stock Incentive Plan of Pryce (Shanghai) Pharmaceutical Technology Development Co., Ltd. reserves and grants some of the first achievements of lifting the sales restriction conditions during the period of lifting the sales restrictions
Prius: Announcement on the 2024 semi-annual profit distribution plan
SMO Clinplus: Announcement on the early termination of the plan of shareholding reduction by shareholders holding 5% or more of the company's shares.
SMO Clinplus: 2023 Annual Equity Distribution Implementation Notice
SMO Clinplus: Announcement on the change in shareholding ratio of shareholders holding 5% or more of the company's shares to 1%
SMO Clinplus: Announcement on the 2023 Profit Distribution Plan
Pris: Pre-disclosure announcement on shareholders holding 5% or more of the company's shares to reduce their shareholding
Prius: Announcement on the completion of the implementation of the plan to increase the actual controller\'s shareholding
Analysis
Price Target
No Data
No Data